الصفحة الرئيسية>>Signaling Pathways>> Proteases>> Lipoxygenase>>S-(+)-Marmesin ((+)-Marmesin)

S-(+)-Marmesin ((+)-Marmesin) (Synonyms: (+)-Marmesin, (S)-Marmesin, NSC 340840)

رقم الكتالوجGC30027

S- (+) -Marmesin ((+) -Marmesin) عبارة عن كومارين طبيعي يظهر نشاط مثبط مزدوج لـ COX-2/5-LOX.

Products are for research use only. Not for human use. We do not sell to patients.

S-(+)-Marmesin ((+)-Marmesin) التركيب الكيميائي

Cas No.: 13849-08-6

الحجم السعر المخزون الكميّة
5 mg
108٫00
متوفر
10 mg
180٫00
متوفر
25 mg
360٫00
متوفر
50 mg
621٫00
متوفر
100 mg
891٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

S-(+)-Marmesin is a natural coumarin, exhibiting COX-2/5-LOX dual inhibitory activity.

S-(+)-Marmesin ((+)-marmesin) shows affinity at the recombinant psoralen synthase, with a Km of 1.5 ± 0.5 μM, exceeding the substrate affinities of other enzymes of the CYP71 subfamily involved in plant secondary metabolism[1]. S-(+)-Marmesin ((+)-marmesin) shows COX-2/5-LOX dual inhibitory activity[2].

[1]. Larbat R, et al. Molecular cloning and functional characterization of psoralen synthase, the first committed monooxygenase of furanocoumarin biosynthesis. J Biol Chem. 2007 Jan 5;282(1):542-54. Epub 2006 Oct 26. [2]. Kim JS, et al. Chemical constituents of the root of Dystaenia takeshimana and their anti-inflammatory activity. Arch Pharm Res. 2006 Aug;29(8):617-23.

مراجعات

Review for S-(+)-Marmesin ((+)-Marmesin)

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for S-(+)-Marmesin ((+)-Marmesin)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.